BACKGROUND: Endothelin (ET)-l is a bronchoconstrictor peptide produced in the airways. It has been implicated in the pathogenesis of asthma and virally mediated airway inflammation and may play a role in exacerbations of chronic obstructive pulmonary disease (COPD). METHODS: Seventy one patients with COPD were followed prospectively and sampled for plasma and sputum ET-1 levels when stable and during an exacerbation. Sputum was also examined for cytokines, human rhinovirus, and Chlamydia pneumoniae. RESULTS: Plasma ET-1 levels were available for 67 patients with stable COPD (mean (SD) 0.58 (0.31) pg/ml); 28 pairs of stable-exacerbation plasma samples had a mean stable ET-1 level of 0.54 (0.30) pg/ml rising to 0.67 (0.35) pg/ml at exacerbation (mean difference 0.13, 95% confidence interval (CI) 0.04 to 0.21, p = 0.004). Plasma ET-1 levels in the 67 patients with stable COPD were inversely correlated with baseline forced expiratory volume in one second (FEV(1); r = -0. 29, p = 0.022) and forced vital capacity (FVC; r = -0.38, p = 0.002). The change in plasma ET-1 levels during an exacerbation correlated with the change in oxygen saturation (SaO(2); r = -0.41, p = 0.036). In 14 stable-exacerbation pairs of sputum samples median stable ET-1 levels were 5.37 (0.97-21.95) pg/ml rising to 34.68 (13.77-51.95) pg/ml during an exacerbation (mean difference 25.14, 95% CI 3.77 to 46.51, p = 0.028). This increase in sputum ET-1 levels correlated with the increase in plasma ET-1 levels (r = 0.917, p = 0.001) and sputum interleukin (IL)-6 levels (r = 0.718, p = 0.013). CONCLUSIONS: Sputum levels of ET-1 rise in COPD patients during an exacerbation and this is reflected by a smaller rise in plasma ET-1 levels. ET-1 may have a role in mediating airway inflammatory changes during exacerbations of COPD.
BACKGROUND:Endothelin (ET)-l is a bronchoconstrictor peptide produced in the airways. It has been implicated in the pathogenesis of asthma and virally mediated airway inflammation and may play a role in exacerbations of chronic obstructive pulmonary disease (COPD). METHODS: Seventy one patients with COPD were followed prospectively and sampled for plasma and sputum ET-1 levels when stable and during an exacerbation. Sputum was also examined for cytokines, human rhinovirus, and Chlamydia pneumoniae. RESULTS: Plasma ET-1 levels were available for 67 patients with stable COPD (mean (SD) 0.58 (0.31) pg/ml); 28 pairs of stable-exacerbation plasma samples had a mean stable ET-1 level of 0.54 (0.30) pg/ml rising to 0.67 (0.35) pg/ml at exacerbation (mean difference 0.13, 95% confidence interval (CI) 0.04 to 0.21, p = 0.004). Plasma ET-1 levels in the 67 patients with stable COPD were inversely correlated with baseline forced expiratory volume in one second (FEV(1); r = -0. 29, p = 0.022) and forced vital capacity (FVC; r = -0.38, p = 0.002). The change in plasma ET-1 levels during an exacerbation correlated with the change in oxygen saturation (SaO(2); r = -0.41, p = 0.036). In 14 stable-exacerbation pairs of sputum samples median stable ET-1 levels were 5.37 (0.97-21.95) pg/ml rising to 34.68 (13.77-51.95) pg/ml during an exacerbation (mean difference 25.14, 95% CI 3.77 to 46.51, p = 0.028). This increase in sputum ET-1 levels correlated with the increase in plasma ET-1 levels (r = 0.917, p = 0.001) and sputum interleukin (IL)-6 levels (r = 0.718, p = 0.013). CONCLUSIONS: Sputum levels of ET-1 rise in COPDpatients during an exacerbation and this is reflected by a smaller rise in plasma ET-1 levels. ET-1 may have a role in mediating airway inflammatory changes during exacerbations of COPD.
Authors: M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki Journal: Nature Date: 1988-03-31 Impact factor: 49.962
Authors: H E Fleming; F F Little; D Schnurr; P C Avila; H Wong; J Liu; S Yagi; H A Boushey Journal: Am J Respir Crit Care Med Date: 1999-07 Impact factor: 21.405
Authors: G W Chalmers; K J Macleod; S Sriram; L J Thomson; C McSharry; B H Stack; N C Thomson Journal: Eur Respir J Date: 1999-06 Impact factor: 16.671
Authors: J A Wedzicha; T A Seemungal; P K MacCallum; E A Paul; G C Donaldson; A Bhowmik; D J Jeffries; T W Meade Journal: Thromb Haemost Date: 2000-08 Impact factor: 5.249
Authors: H Ehrenreich; R W Anderson; C H Fox; P Rieckmann; G S Hoffman; W D Travis; J E Coligan; J H Kehrl; A S Fauci Journal: J Exp Med Date: 1990-12-01 Impact factor: 14.307
Authors: Sumanth Polikepahad; Masudul Haque; Joseph Francis; Rustin M Moore; Changaram S Venugopal Journal: Can J Vet Res Date: 2008-07 Impact factor: 1.310
Authors: Riccardo Polosa; Mario Malerba; Rossella R Cacciola; Jaymin B Morjaria; Cinzia Maugeri; Gaetano Prosperini; Raimondo Gullo; Lucia Spicuzza; Alessandro Radaeli; Giuseppe U Di Maria Journal: Intern Emerg Med Date: 2011-06-10 Impact factor: 3.397
Authors: Meghan E Fitzpatrick; Mehdi Nouraie; Matthew R Gingo; Danielle Camp; Cathy J Kessinger; James B Sincebaugh; Andrew Clarke; John W Ries; Eric C Kleerup; Lawrence Kingsley; Alison Morris Journal: AIDS Date: 2016-06-01 Impact factor: 4.177